Xtent: Sizing Up the Drug-Eluting Stent Market
This article was originally published in Start Up
Executive Summary
Xtent founders set out to figure out how a small company could reasonably compete with the likes of Boston Scientific and J&J, who have built such a huge lead in the short time they've had drug-eluting stents. Xtent has developed a next generation system that is designed to eliminate catheter exchanges entirely. Specifically, Xtent's stent delivery platform enables cardiologists to treat multiple lesions of varying lengths with a single device during a single catheter insertion.